Alvaro Uribe is found guilty of witness tampering and procedural fraud, reports NICK MACWILLIAM
Public pharma v abusive prices: the case of the latest HIV-prevention drug
ALAN ROSSI SILVA argues that Gilead’s HIV prevention drug, while promising, highlights systemic failures in the pharmaceutical industry, showing the need to shift towards state-owned drug development and production
An electron micrograph of HIV-1 virus particles (colourized red) replicating from an HIV-infected H9 T-cell (blue)
On the anniversary of the implementation of the 1833 Slavery Abolition Act, ROGER McKENZIE warns that the legacy of black enslavement still looms in the Caribbean and beyond
Starmer’s decision to recognise Palestine only as long as Israel continues to massacre its inhabitants has been met with outrage, writes LINDA PENTZ GUNTER
The creative imagination is a weapon against barbarism, writes KENNY COYLE, who is a keynote speaker at the Manifesto Press conference, Art in the Age of Degenerative Capitalism, tomorrow at the Marx Memorial Library & Workers School in London
RAMZY BAROUD explains why the world can no longer ignore Palestine
Starmer’s decision to suspend Diane Abbott yet again demonstrates a determination to maintain and propagate a hierarchy of racism, writes CLAUDIA WEBBE
LENACAPAVIR, an injectable antiretroviral drug developed by Gilead Sciences, recently made headlines after a Phase 3 clinical trial in South Africa and Uganda showed it to be 100 per cent effective in preventing HIV among women and adolescent girls.
Though hailed as a breakthrough in HIV prevention, lenacapavir serves as a stark reminder of the problems with the pricing of life-saving medicines.
While further data from this study and results from studies involving other populations are needed, lenacapavir could be considered the most durable HIV prevention method to show efficacy among women — a population for who biomedical HIV prevention evidence has been severely limited.
Similar stories
When privatisation is already so deeply embedded in the NHS, we can’t just blindly argue for ‘more funding’ to solve its problems, explain ESTHER GILES, NICO CSERGO, BRIAN GIBBONS and RATHI GUHADASAN
Despite miraculous trial results showing new treatment could halt transmission, corporate greed and patent laws condemn millions to preventable infection and death, write ROX MIDDLETON, LIAM SHAW and MIRIAM GAUNTLETT
Labour’s controversial plan to put the overweight and unemployed on the ‘skinny jab’ Mounjaro should set alarm bells ringing once we look into some of the research into the drug and the company set to supply it, warns CLAUDIA WEBBE
Keep Our NHS Public campaigner GREG DROPKIN dissects how Lord Darzi’s recommendations align with Starmer’s plans for NHS ‘reform,’ warning of creeping privatisation under the guise of modernisation